TCGA analysis showed that the BRCA1 and BRCA2 mutations in 22 % of the high grade serous ovarian cancer (HGS-OvCa) samples triggered a wide range of aberrations in DNA damage repair pathways, such as poly (ADP-ribose) polymerase inhibitors (PARPi) [11]. This evidence concerns the gene BRCA2 and ovarian serous adenocarcinoma.